大麻使用的神经特征:通过全脑功能网络连接逆转认知衰老
Zening Fu1, Kent Hutchison2, Armin Iraji3
1Georgia Institute of Technology, Emory University and Georgia State University.
Research square
|August 6, 2025
概括
老年人使用大麻与类似于年轻人的大脑网络模式和增强的认知功能有关. 这表明大麻素可能会影响大脑衰老和神经退行.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 由于社会变化和公认的治疗潜力,老年人中大麻使用量的增加.
- 认知衰老是这群人群的一个主要问题,与大麻使用共享神经通路.
- 大麻对老年大脑和认知的影响尚不清楚.
研究的目的:
- 通过使用大规模数据,研究大麻使用,衰老和认知功能之间的关系.
- 调查大麻使用,衰老和大脑功能网络连接 (FNC) 之间的相关性.
- 为了阐明对大脑神经成像模式的交互效应.
主要方法:
- 使用了大规模的英国生物库数据 (>25,000名参与者).
- 分析了大麻使用,规范性衰老和认知功能之间的相关性.
- 专注于大脑功能网络连接 (FNC) 模式.
主要成果:
- 大麻使用和健康的衰老显示了重叠的大脑网络配置,特别是在皮下,感觉运动和小脑区域.
- 大麻使用者在多个认知领域表现出卓越的表现.
- 大麻的认知效应同时在各种大脑系统中观察到.
结论:
- 大麻使用者表现出与年轻人相关的大脑网络特征.
- 在大麻使用者中观察到增强的认知能力.
- 大麻素可能通过神经脱差和补偿机制在神经退行中发挥调节作用.
相关概念视频
Long-term Depression
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Long-term Depression
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over time, all...
Calcium Ion Concentration Mechanism
If over time, all...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...


